Swiss GRC Day 2025: Governance, Risk and Compliance as a Strategic Imperative
LUCERNE, Switzerland--(BUSINESS WIRE)-- Swiss GRC Day 2025 brought together specialists and managers from the DACH region at Zurich Airport. The conference offered insights into current developments in governance, risk and compliance (GRC) – from cyber risks and regulatory requirements to artificial intelligence and leadership culture.
Swiss GRC Day 2025 brought together leading minds in governance, risk, and compliance from across the DACH region. The conference highlighted how GRC is evolving from a control function into a strategic driver.
Share
'GRC is not a control instrument, but a strategic management system,' emphasized Besfort Kuqi, co-founder and CEO of Swiss GRC, at the opening of the Swiss GRC Day 2025. Companies must actively prepare for uncertainties, use technological innovations responsibly and strengthen their cultural resilience.
The opening keynote speech by Nikolai Tsenov, Head Strategy & Business Development at Swiss GRC, provided a historical look back at the Lisbon earthquake of 1755. He illustrated how decisive action, strategic leadership and courageous reforms formed the basis for resilience and governance centuries ago - principles that are more relevant today than ever.
The program offered a strong combination of theory, strategy and practice. Christian Weiss, Head of Enterprise Risk at Skyguide, described how a temporary airspace shutdown over Switzerland could be managed with clear decision-making processes and practiced crisis structures.
Marc Etienne Cortesi, Group CISO of the Baloise Group, demonstrated the extent to which digital dependencies have increased. Using a cyberattack as an example, he explained how vulnerable supply chains are - and how the NIST C-SCRM Framework can help to prioritize risks and build resilience.
Technological change and its ethical and regulatory impact were also in focus. Marinela Bilic-Nosic, Partner at EY Germany, advocated for company-wide AI governance, especially for autonomous systems. David Rosenthal, Partner at VISCHER AG, showed how the EU AI Act can be applied in an innovation-friendly way through clear responsibilities, staged approvals, and trained decision-makers.
Marc Gröflin, Head of Internal Audit at the Swiss National Bank, presented a combined assurance model that creates more transparency and real added value by closely coordinating audit, risk, ICS and compliance.
Sandra Middel, Chief Ethics and Compliance Officer of the Axpo Group, provided the final impulse. She focused on the role of corporate culture and emphasized the importance of lived values, responsibility in everyday life and leadership by example.
The contributions made one thing clear: GRC is a networked, strategic management approach – and a key success factor for organizations in a complex, dynamic world.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
SIGNING DAY SPORTS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Signing Day Sports, Inc.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of Signing Day Sports, Inc. (NYSE: SGN) and One Blockchain LLC. Upon closing of the proposed transaction, Signing Day shareholders are expected to own approximately 8.5% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Signing Day shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
2 hours ago
- Business Wire
INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Broadmark Realty Capital Inc., Ready Capital Corporation, Others and Announces Opportunity for Investors with Substantial Losses to Lead Lawsuit – BRMK; RC
SAN DIEGO--(BUSINESS WIRE)--The law firm of Robbins Geller Rudman & Dowd LLP announces that holders of Broadmark Realty Capital Inc. (NYSE: BRMK) common stock as of the record date of the May 2023 merger between Broadmark and Ready Capital Corporation (NYSE: RC) ('Merger'), have until July 28, 2025 to seek appointment as lead plaintiff of the Broadmark class action lawsuit. Captioned Grant v. Broadmark Realty Capital, No. 25-cv-01013 (W.D. Wash.), the Broadmark class action lawsuit charges Broadmark, Ready Capital, certain of Broadmark's and Ready Capital's top executives and directors, and Ready Capital's external asset manager with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Broadmark class action lawsuit, please provide your information here: CASE ALLEGATIONS: Broadmark and Ready Capital are real estate investments trusts. On May 30, 2023, Broadmark shareholders voted to approve the merger of Broadmark and Ready Capital, which closed the next day. The Broadmark class action lawsuit alleges that the proxy statement used to solicit the support of Broadmark shareholders for the Merger contained false and/or misleading statements and/or failed to disclose that: (i) a material portion of borrowers within Ready Capital's originated portfolio were experiencing significant financial distress due to high interest rates that had increased their borrowing costs; (ii) an oversupply of multifamily properties in Ready Capital's markets of operation had severely limited the ability of Ready Capital borrowers to raise their rents by the amounts necessary to cover their growing debt costs; (iii) a major development project acquired in Ready Capital's acquisition of Mosaic Real Estate Credit, LLC, Mosaic Real Estate Credit TE, LLC, and MREC International Incentive Split, LP (a Ritz-Carlton located in Portland, Oregon), which accounted for approximately $500 million of Ready Capital's acquired loan portfolio, had experienced catastrophic setbacks since its inception, including significant cost overruns, construction delays, and funding shortfalls; (iv) as a result, Ready Capital's Current Expected Credit Loss reserves and expected credit losses were materially understated; and (v) consequently, Ready Capital's financial projections regarding Ready Capital's Distributable Earnings per share, dividends per share, and book value per share had no basis in fact when made. The price of Ready Capital stock has remained significantly below the Merger price as of the time the Broadmark class action lawsuit was filed. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who held Broadmark common stock as of the record date of the Merger to seek appointment as lead plaintiff in the Broadmark class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Broadmark class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Broadmark class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Broadmark class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
Business Wire
5 hours ago
- Business Wire
Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program. This initiative will harness Tempus' proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learning capabilities to develop an AI enabled-diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality. Over the past decade, Tempus has built a multimodal data library of over 40 million research records, including more than 1.5 million records with matched clinical data linked with genomic information, 2 million records with imaging data, and approximately 300,000 records with genomic and whole transcriptomic data. The scale and size of this data library will allow the company to uncover groundbreaking discoveries that were previously out of reach. Fuses will accelerate Tempus' comprehensive testing portfolio, expanding its suite of AI-enabled diagnostics. Insights from Fuses will be developed into clinically validated algorithmic diagnostics that may enable highly personalized care, such as identifying patients unlikely to respond to approved therapies or those at risk of severe treatment-related events. Tempus has already begun this work with last year's launch of its Immune Profile Score (IPS) a multimodal biomarker that can be used as a prognostic indicator for adult patients with metastatic pan-solid tumors eligible for immune checkpoint inhibitor (ICI)-based therapy. 'We have spent the last ten years building, scaling, and curating one of the most comprehensive datasets in our industry, and now we are well positioned to develop the world's largest diagnostic model, designed to answer critical, unsolved questions and make our diagnostics smarter and more personalized,' said Eric Lefkofsky, Founder and CEO of Tempus. 'We are on the brink of delivering tangible, transformative change in matching the right therapies to the right patients - making personalized care a reality for millions.' The foundational model behind Fuses is learning generalizable rules determining prognosis and drug benefit in real-world practice. With the goal of furthering researchers' understanding of why certain clinical trials fail, identify new indications for investigational drugs, optimize trial design, and uncover combination therapies to broaden patient benefit. By revealing biomarker rules, the model may also surface mechanisms of drug response and resistance to inspire a new generation of companion diagnostics and therapeutic research. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of Fuses and its insights in oncology clinical care and therapeutic research and discovery, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
